描述
Product Specifications
Attribute | Details |
---|---|
Product Name | Sildenafil Citrate Orodispersible Tablet (Huiren® / Likexin) |
Generic Name | Sildenafil Citrate |
CAS Number | 171599?83?0 patents.google.com+4gz.zbzxyy.com+4nmpa.gov.cn+4 |
Molecular Formula | C??H??N?O?S · C?H?O? |
Molecular Weight | ?666.7?g/mol |
Dosage Form | Oro?dispersible tablet (ODT) |
Strength | 50?mg per tablet |
Pack Size | 1 tablet per box |
Approval Number | China NMPA H20244673 |
Product Code | 86910323000369 |
Manufacturer | Jiangxi Huiren Pharmaceutical Co., Ltd. |
Barcode | 6937999607160 |
Storage | Store at 15–25?°C; protect from light and moisture |
Intended Use | Laboratory research only |
Mechanism of Action
Sildenafil selectively inhibits PDE5, preventing breakdown of cGMP in smooth muscle cells, leading to enhanced nitric oxide (NO)-mediated vasodilation, especially in penile and pulmonary vasculature.
Research Applications & Pharmacology
-
Erectile Dysfunction (ED) Models: Widely used to assess cGMP-mediated signaling and vascular responses .
-
Pulmonary Arterial Hypertension: Employed to investigate PDE5’s role in pulmonary vascular dilation.
-
Pharmacokinetics of ODTs: Orodispersible formulations dissolve rapidly in seconds—promoting fast absorption without water .
-
Clinical Parameters: Typical onset ~20 minutes, duration ~2 hours; metabolic clearance by CYP3A4/5; excreted primarily in feces and urine .
Safety Profile & Handling
-
Common Adverse Effects: Headache, flushing, nasal congestion, dyspepsia, and mild dizziness .
-
Drug Interactions: Avoid concurrent administration with nitrates or NO donors due to risk of severe hypotension .
-
Contraindications: Not suitable for models involving cardiovascular compromise or concurrent PDE5-inhibiting agents.
-
Handling Instructions: Store under recommended conditions, use protective PPE, discard as per institutional safety protocols. This product is strictly for research and not for administration.
评价
目前还没有评价